Cargando…
When dormancy fuels tumour relapse
Tumour recurrence is a serious impediment to cancer treatment, but the mechanisms involved are poorly understood. The most frequently used anti-tumour therapies—chemotherapy and radiotherapy—target highly proliferative cancer cells. However non- or slow-proliferative dormant cancer cells can persist...
Autores principales: | Santos-de-Frutos, Karla, Djouder, Nabil |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209066/ https://www.ncbi.nlm.nih.gov/pubmed/34135460 http://dx.doi.org/10.1038/s42003-021-02257-0 |
Ejemplares similares
-
Tumour dormancy in breast cancer: an update
por: Brackstone, Muriel, et al.
Publicado: (2007) -
Transit-amplifying cells control R-spondins in the mouse crypt to modulate intestinal stem cell proliferation
por: Chaves-Pérez, Almudena, et al.
Publicado: (2022) -
The Role of the Innate Immune System in Cancer Dormancy and Relapse
por: Chernosky, Noah M., et al.
Publicado: (2021) -
Breast Cancer Metastatic Dormancy and Relapse: An Enigma of Microenvironment(s)
por: Elkholi, Islam E., et al.
Publicado: (2022) -
Tumour dormancy and clinical implications in breast cancer
por: Gelao, L, et al.
Publicado: (2013)